Orin Hirschman
Directeur Général chez AIGH Capital Management LLC
Fortune : 374 448 $ au 31/05/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Aaron Isaiah Martin | M | - |
AIGH Capital Management LLC
 AIGH Capital Management LLC Investment ManagersFinance AIGH Capital Management LLC (AIGH) is a SEC-registered investment advisor headquartered in Baltimore, Maryland. The firm was founded in 2011 and is owned by AIGH Investment Partners LLC. AIGH provides discretionary investment advisory services to private investment funds and sub advises private funds. | 13 ans |
| Yitzchak Jacobovitz | M | 48 |
AIGH Capital Management LLC
AIGH Capital Management LLC Investment ManagersFinance AIGH Capital Management LLC (AIGH) is a SEC-registered investment advisor headquartered in Baltimore, Maryland. The firm was founded in 2011 and is owned by AIGH Investment Partners LLC. AIGH provides discretionary investment advisory services to private investment funds and sub advises private funds. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Irach Taraporewala | M | 68 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 7 ans |
| Samuel Backenroth | M | 39 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 9 ans |
| Jason Scott Slakter | M | 66 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 5 ans |
| Ira Greenstein | M | 63 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 10 ans |
| Thomas M. Riedhammer | M | 76 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 ans |
| June Almenoff | M | 67 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 ans |
| Lindsay Rosenwald | M | 68 |
D.H. Blair & Co., Inc.
| 5 ans |
| Glenn L. Stoller | M | 60 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | - |
| Peter K. Kaiser | M | - |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | - |
| Michael Ferguson | M | 53 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 2 ans |
| Marshall Staiman | M | - |
Touro College
| 4 ans |
| Andrew Limpert | M | 53 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 8 ans |
| David Drillick | M | 53 |
Touro College
| 4 ans |
| Randy Scott Zelin | M | 59 |
Touro College
| 3 ans |
| James Mitarotonda | M | 69 |
D.H. Blair & Co., Inc.
| 4 ans |
| Asher Zwebner | M | 58 |
Touro College
| 4 ans |
| Steven Yehuda Moskowitz | M | 60 |
Touro College
| 4 ans |
| Mark R. Basile | M | 65 |
Touro College
| 3 ans |
| Avner Ingerman | M | 60 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 21 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Orin Hirschman
- Réseau Personnel
